Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma

NANot yet recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DEVICE

ONCOLAXY Follow-up

"The operation of Oncolaxy© is based on the principle of e-PRO (electronic patient reported outcome) which is able to assess the symptoms declared by patients treated for cancer, to detect an evolution, a recurrence or the toxicity of a therapy. Alerts are sent to the healthcare team if the algorithm detects suspicious symptoms or worsening of these symptoms.~Oncolaxy© records symptoms using an electronic questionnaire that allows them to be graded. Questionnaires are sent out on a regular basis. The algorithm analyzes the responses and processes them taking into account the score of the response and its evolution over time. The combination of the results makes it possible to send information to the healthcare teams in charge of the patient that will alert them, enlighten them and help them guide their decisions which remain under their sole control. The summary of the results can be viewed at any time on a dashboard."

Trial Locations (5)

33077

Polyclinique Bordeaux Nord Aquitaine, Bordeaux

44200

Hôpital Privée du Confluent, Nantes

44600

Centre Hospitalier de St Nazaire, Saint-Nazaire

67000

Centre de radiothérapie de Robertsau, Strasbourg

72000

Clinique Victor Hugo/Centre Jean Bernard/ILC, Le Mans

Sponsors
All Listed Sponsors
collaborator

Resilience

INDUSTRY

collaborator

Incyte Corporation

INDUSTRY

lead

Weprom

OTHER

NCT05298293 - Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma | Biotech Hunter | Biotech Hunter